Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Investigational New Drugs
Erschienen in: Investigational New Drugs 3/2018

08.11.2017 | PRECLINICAL STUDIES

Cyclodextrin polymers as nanocarriers for sorafenib

verfasst von: Valentina Giglio, Maurizio Viale, Vittorio Bertone, Irena Maric, Rita Vaccarone, Graziella Vecchio

Erschienen in: Investigational New Drugs | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Summary

Polymeric nanoparticles based on cyclodextrins are currently undergoing clinical trials as new promising nanotherapeutics. In light of this interest, we investigated cyclodextrin cross-linked polymers with different lengths as carriers for the poorly water-soluble drug sorafenib. Both polymers significantly enhanced sorafenib solubility, with shorter polymers showing the most effective solubilizing effect. Inclusion complexes between sorafenib and the investigated polymers exhibited an antiproliferative effect in tumor cells similar to that of free sorafenib. Polymer/Sorafenib complexes also showed lower in vivo tissue toxicity than with free sorafenib in all organs. Our results suggest that the inclusion of sorafenib in polymers represents a successful strategy for a new formulation of this drug.
Literatur
1.
Popielec A, Loftsson T (2017) Effects of cyclodextrins on the chemical stability of drugs. Int J Pharm 531:532–542
2.
Khan AR, Forgo P, Stine KJ, D’Souza VT (1998) Methods for selective modifications of cyclodextrins. Chem Rev 98:1977–1996
3.
Oliveri V, Vecchio G (2016) Cyclodextrins as protective agents of protein aggregation: an overview. Chem Asian J 11:1648–1657CrossRefPubMed
4.
Heidel JD, Schluep T (2012) Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv ID 262731:17
5.
Arima H, Hayashi Y, Higashi T, Motoyama K (2015) Recent advances in cyclodextrin delivery techniques. Expert Opin Drug Deliv 12:1425–1441CrossRefPubMed
6.
Giglio V, Oliveri V, Viale M, Gangemi R, Natile G, Intini FP, Vecchio G (2015) Folate–cyclodextrin conjugates as carriers of the platinum(IV) complex LA-12. ChemPlusChem 80:536–543
7.
Bellia F, La Mendola D, Pedone C, Rizzarelli E, Saviano M, Vecchio G (2009) Selectively functionalized cyclodextrins and their metal complexes. Chem Soc Rev 38:2756–2781CrossRefPubMed
8.
Lakkakula JR, Maçedo Krause RW (2014) A vision for cyclodextrin nanoparticles in drug delivery systems and pharmaceutical applications. Nanomedicine 9:877–894CrossRefPubMed
9.
Van de Manakker F, Vermonden T, Van Nostrum CF, Hennink WE (2009) Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. Biomacromolecules 10:3157–3175CrossRefPubMed
10.
Vulic K, Shoichet MS (2014) Affinity-based drug delivery systems for tissue repair and regeneration. Biomacromolecules 15:3867–3880
11.
Jones RK, Caldwell JE, Brull SJ, Soto RG (2008) Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 109:816–824CrossRefPubMed
12.
13.
14.
Avnesh S, Thakor MD, Sanjiv S, Gambhir MD (2013) Nanooncology: the future of cancer diagnosis and therapy. Cancer J Clin 63:395–418CrossRef
15.
Fülöp Z, Kurkov SV, Nielsen TT, Larsen KL, Loftsson T (2012) Self-assembly of cyclodextrins: formation of cyclodextrin polymer-based nanoparticles. J Drug Deliv Sci Technol 22:215–222
16.
Oliveri V, Bellia F, Vecchio G (2017) Cyclodextrin nanoparticles bearing 8-hydroxyquinoline ligands as multifunctional biomaterials. Chem Eur J 23:442–4449CrossRef
17.
Swaminathan S, Cavalli R, Trotta F (2016) Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:579–601CrossRefPubMed
18.
Zhu W, Li Y, Liu L, Chen Y, Wang C, Xi F (2010) Supramolecular hydrogels from cisplatin-loaded block copolymer nanoparticles and α-Cyclodextrins with a stepwise delivery property. Biomacromolecules 11:3086–3092CrossRefPubMed
19.
Oliveri V, Bellia F, Viale M, Maric I, Vecchio G (2017) Linear polymers of β and γ cyclodextrins with a polyglutamic acid backbone as carriers for doxorubicin. Carbohydr Polym. 177:355–360
20.
Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070CrossRefPubMedPubMedCentral
21.
Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME (2016) CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. PNAS 113:3850–3854CrossRefPubMedPubMedCentral
22.
Hu C-MJ, Fang RH, Luk BT, Zhang L (2014) Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nano 6:65–75
23.
Gidwani B, Vyas A (2014) Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer. Colloids Surf B 114:130–137
24.
Giglio V, Sgarlata C, Vecchio G (2015) Novel amino-cyclodextrin cross-linked oligomer as efficient carrier for anionic drugs: a spectroscopic and nanocalorimetric investigation. RSC Adv 5:16664–16671CrossRef
25.
Kanwar JR, Long BM, Kanwar RK (2011) The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 18:2079–2085CrossRefPubMed
26.
Anand R, Malanga M, Manet I, Manoli F, Tuza K, Aykac A, Ladaviere C, Fenyvesi E, Vargas-Berenguel A, Gref R, Monti S (2013) Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. Photochem Photobiol Sci 12:1841–1854CrossRefPubMed
27.
Folch-Cano C, Yazdani-Pedram M, Olea-Azar C (2014) Inclusion and functionalization of polymers with cyclodextrins: current applications and future prospects. Molecules 19:14066–14079CrossRefPubMed
28.
Sherje AP, Dravyakar BR, Kadam D, Jadhav M (2017) Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym 173:37–49CrossRefPubMed
29.
Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3:703–717
30.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F (2014) Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opin Drug Saf 13:663–673CrossRefPubMed
31.
European Medicines Agency. Sorafenib—EPAR Scientific Discussion (2010)
32.
Almeida e Sousa L, Reutzel-Edens SM, Stephenson GA, Taylor LS (2015) Assessment of the amorphous “solubility” of a Group of Diverse Drugs Using new Experimental and Theoretical Approaches. Mol. Pharmaceutics 12:484–−495
33.
Liu C, Chen Z, Chen Y, Lu J, Li Y, Wang S, Wu G, Qian F (2016) Improving oral bioavailability of Sorafenib by optimizing the “spring” and “parachute” based on molecular interaction mechanisms. Mol Pharm 13:599–608CrossRefPubMed
34.
Bondì ML, Scala A, Sortino G, Amore E, Botto C, Azzolina A, Balasus D, Cervello M, Mazzaglia A (2015) Nanoassemblies based on supramolecular complexes of nonionic amphiphilic cyclodextrin and sorafenib as effective weapons to kill human HCC cells. Biomacromolecules 16:3784–3791
35.
Zhang N, Zhang B, Gong X, Wang T, Liu Y, Yang S (2016) In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. Int J Nanomedicine 11:2329–2343CrossRefPubMedPubMedCentral
36.
Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B, Goldwasser F (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9:275–287CrossRefPubMed
37.
Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K (2015) Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: an autopsy case report. Oncol Lett 9:1633–1636CrossRefPubMedPubMedCentral
38.
39.
Guo Y, Zhong T, Duan X-C, Zhang S, Yao X, Yin Y-F, Huang D, Ren W, Zhang Q, Zhang X (2017) Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix. Drug Deliv 24:270–277CrossRefPubMed
40.
Giglio V, Viale M, Monticone M, Aura AM, Spoto G, Natile G, Intini FP, Vecchio G (2016) Cyclodextrin polymers as carriers for the platinum-based anticancer agent LA-12. RSC Adv 6:12461–12466CrossRef
41.
Loftsson T, Hreinsdottir D, Masson M (2005) Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 302:18–28CrossRefPubMed
42.
Oliveri V, Puglisi A, Viale M, Aiello C, Vecchio G, Clarke J, Milton J, Spencer J (2013) New cyclodextrin-bearing 8-hydroxyquinoline ligands as multifunctional molecules. Chem Eur J 19:13946–13955CrossRefPubMed
43.
Mariggiò MA, Cafaggi S, Ottone M, Parodi B, Vannozzi MO, Parodi A, Mandys V, Viale M (2004) Inhibition of cell growth: induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4- amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate. Invest New Drugs 22:3–16
44.
Layre AM, Gosselet NM, Renard E, Sebille B, Amiel C (2003) Comparison of the complexation of cosmetic and pharmaceutical compounds with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and water-soluble-β-cyclodextrin-co-epichlorohydrin polymers. J. Inclusion Phenomen Macrocyclic Chem 43:311–317CrossRef
45.
Martin R, Sánchez I, Cao R, Rieumont J (2006) Solubility and kinetic release studies of naproxen and ibuprofen in soluble Epichlorohydrin-β-cyclodextrin polymer. Supramol Chem 18:627–631CrossRef
46.
Fülöp Z, Nielsen TT, Larsen KL, Loftsson T (2013) Dextran-based cyclodextrin polymers: their solubilizing effect and self-association. Carbohydr Polym 97:635–642CrossRefPubMed
47.
Hashemi F, Tamaddon AM, Yousefi GH, Farvadi F (2012) Effect of pH on Solubilisation of Practically Insoluble Sorafenib by Classic and Stealth Polyamidoamine (PAMAM) Dendrimers and β–cyclodextrin. Proc NAP 1:02NNBM06
48.
Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum based anticancer agents. J Pharm Sci 98:2299–2316CrossRefPubMed
49.
Viale M, Rossi M, Russo E, Cilli M, Aprile A, Profumo A, Santi P, Fenoglio C, Cafaggi S, Rocco M (2015) Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model. Invest New Drugs 33:1151–1161
Metadaten
Titel
Cyclodextrin polymers as nanocarriers for sorafenib
verfasst von
Valentina Giglio
Maurizio Viale
Vittorio Bertone
Irena Maric
Rita Vaccarone
Graziella Vecchio
Publikationsdatum
08.11.2017
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 3/2018
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0538-9

Weitere Artikel der Ausgabe 3/2018

Investigational New Drugs 3/2018 Zur Ausgabe

SHORT REPORT

Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report

PHASE I STUDIES

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer

PHASE I STUDIES

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

PHASE II STUDIES

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study

PRECLINICAL STUDIES

Contribution of reactive oxygen species to the anticancer activity of aminoalkanol derivatives of xanthone

PHASE III STUDIES

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise